Getting rid of refractory hemophilia.
In a prospective randomized, multicenter study of immune tolerance induction(ITI) in patients with hemophilia A refractory to replacement therapy after the development of alloantibodies that inhibit factor VIII (FVIII) activity, Hay and DiMichele compared two regimens, a low dose of FVIII (50 IU/Kg thrice weekly)or a high-dose (200 IU/kg daily
IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation.
Pier Mannuccio
PM
Mannucci